HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferrero, E. Articles by Zocchi, M. R. Search for Related Content PubMed PubMed Citation Articles by Ferrero, E. Articles by Zocchi, M. R.

uPA/uPAR System Is Active in Immature Dendritic Cells Derived from CD14⁺CD34⁺ Precursors and Is Down-Regulated upon Maturation¹

Elisabetta Ferrero^2,*, Katuscia Vettoretto^*, Attilio Bondanza^*, Antonello Villa, Massimo Resnati, Alessandro Poggi and Maria Raffaella Zocchi^*

^* Laboratory of Tumor Immunology and Department of Biology and Biotechnology, San Raffaele Scientific Institute, Milan, Italy; Department of Pharmacology, Consiglio Nazionale delle Ricerche Cytopharmacology, and B. Ceccarelli Centers, Milan, Italy; and Laboratory of Immunopathology, National Institute for Cancer Research and Advanced Biotechnology Center, Genoa, Italy

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
We recently described a subset of peripheral CD14⁺CD34⁺ cells able to migrate across endothelial cell monolayers and differentiate into immunostimulatory dendritic cells (DC). In this paper we show that immature DC derived from CD14⁺CD34⁺ precursors are also capable of reverse transendothelial migration and extracellular matrix (ECM) invasion using the urokinase plasminogen activator receptor (uPAR). We found that these cells respond to macrophage-inflammatory protein (MIP)-1, enhancing their ability to invade ECM and supporting the idea that immature DC are selectively recruited at the site of inflammation to expand the pool of APCs. Interestingly, MIP-1 was also capable of preventing the decreased matrix invasion observed by blocking uPAR, suggesting that the uPA/uPAR system and MIP-1 cooperate in driving immature DC migration through the subendothelial matrix. Upon exposure to maturating stimuli, such as TNF-, CD14⁺CD34⁺-derived DC enhance their APC function and decrease the capacity of invading ECM; these changes are accompanied by altered expression and function of uPAR. Moreover, mature DC shift their sensitivity from MIP-1 to MIP-3, enhancing their transendothelial migration capability in response to the latter chemokine. Our data support the hypothesis that bloodborne DC can move through ECM toward the site of pathogen entry where they differentiate into fully mature APCs with their motility and function regulated by microenvironmental stimuli, including MIP-1, MIP-3, and TNF-.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Dendritic cells (DC)³ are professional APCs strategically located in the sites of Ag entry, either in epithelial microenvironment or in lymphoid organs (1, 2). They are thought to derive from precursors which undergo multiple distinct pathways of differentiation depending on the cytokine(s) released in the peripheral tissues where they localize (3, 4). At least two pathways of DC differentiation have been described: thymic DC appear to originate from a hematopoietic progenitor with lymphoid but not myeloid potential, whereas DC related to Langerhans cells can be generated in vitro from myeloid precursors using GM-CSF (5, 6, 7, 8). Human myeloid progenitors cultured with GM-CSF plus TNF- give rise to DC with phenotypic features of Langerhans cells and a monocyte-derived type of DC which induces the production of IgM by activated B cells (5, 9).

Circulating monocytes or bone marrow precursors extravasate to enter tissues, such as tonsils, Peyer’s patches, or epidermis, where they differentiate into macrophages or DC upon inflammatory or immunological stimuli (10, 11). Once DC have encountered the Ag, they undergo full maturation and recirculate through the afferent lymph stream to the T cell-rich areas of the regional draining lymph nodes where Ag presentation takes place (12). Thus, both immature and mature DC should be able to modify their transendothelial migratory ability and matrix invasion properties, depending on the stage of differentiation, the microenvironment, and the presence and capture of the Ag. To accomplish this purpose, DC precursors follow the well-known step-wise model of rolling mediated by selectins (13) and cell adhesion involving integrins (14, 15) and migration (13, 16). The last step is also dependent on the ability of migrating cells to degrade and subsequently invade the subendothelial extracellular matrix (ECM) (13, 17). It is believed that the urokinase plasminogen activator (uPA)/uPAR system plays a critical role in favoring the directional migration of leukocytes from the bloodstream to peripheral tissues, driving leukocytes through subendothelial ECM (18, 19).

We have recently described a subset of CD14⁺CD34⁺ precursors capable of transendothelial migration and differentiation into immunostimulatory DC (20). In this paper we show that immature DC derived from such precursors use the uPA/uPAR system to invade the subendothelial matrix and reverse transmigrate across endothelial monolayers. They also respond to chemotactic agents, such as macrophage-inflammatory protein (MIP)-1. Upon maturation induced by TNF-, CD14⁺CD34⁺-derived DC become potent APCs, shift their sensitivity to chemokines from MIP-1 to MIP-3, and significantly reduce their ability to migrate through ECM. These changes are accompanied by a decreased usage of the uPA/uPAR system.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cell isolation and culture

CD34⁺ and CD34^- cell subsets were fractionated from peripheral blood CD14⁺ cells using immunomagnetic beads (Dynal, Milan, Italy) as described (20, 21). Cells were cultured in RPMI 1640 medium supplemented with 2 mM L-glutamine, 100 IU/ml penicillin and 100 µg/ml streptomycin (Biochrom, Berlin, Germany), 10% heat-inactivated FCS (PAA Labour, Linz, Austria), and 40 ng/ml recombinant GM-CSF (Shering-Plough, Milan, Italy) (20) for 5–7 days to generate DC. In some experiments, TNF- (100 ng/ml, Genzyme, Boston, MA) was added to DC cultures during the last 48 h to obtain mature DC. Media were endotoxin-free as shown by the Limulus lysate colorimetric assay (PBI, Milan, Italy).

Immunofluorescence and confocal microscopy

A total of 10⁵ cells/sample were stained with the various mAbs and then by the anti-isotype-specific FITC- or PE-conjugated goat anti-mouse Igs (GAM) (Zymed Laboratories, San Francisco, CA). The anti-uPAR R2 and R3 mAbs were kindly provided by E. Rønne and G. Høyer-Hanse (K. Danø Finsen Laboratory, Copenhagen, Denmark), whereas the anti-HLA-DR (class II) mAb was a gift from R. Accolla (ABC, Genoa, Italy). The anti-CD80/B7.1 and the anti-CD86/B7.2 mAbs were purchased from Becton Dickinson (Mountain View, CA) and the anti-CD54/ICAM-1 mAb was purchased from Immunotech (Luminy, France). Samples were run on a FACStar^Plus that was equipped with an argon-ion laser (Becton Dickinson) and gated to exclude nonviable cells. At least 5000 events/sample were analyzed. Results are expressed as Log green fluorescence intensity (arbitrary units, a.u.) vs number of cells. Cells to be examined by confocal microscopy were grown on glass coverslips, fixed in 2% paraformaldehyde, and stained with the indicated mAbs and then with FITC-GAM or tetramethylrhodamine isothiocyanate/GAM (TRITC-GAM; Zymed). Coverslips were then mounted in 50% glycerol-PBS. Microscopic analysis was conducted in a Bio-Rad MRC 1000 confocal scanning microscope (Bio-Rad Laboratories, Milan, Italy) and fluorescence images were recorded on Kodak T-Max 100 film using a Focus Imagecorder Plus (Focus Graphics, Foster City, CA) (22).

uPAR content was also measured in the supernatants of DC obtained from GM-CSF cultures (immature DC), exposed to TNF- for the last 48 h (mature DC), or after digestion with phosphoinositide-specific phospholipase C (PI-PLC) (2 U/ml; Sigma, St. Louis, MO) for 2 h at 37°C with a sandwich ELISA as described (23).

Direct and reverse transendothelial migration and matrix invasion assay

Transmigration of radiolabeled (⁵¹Cr; NEN, Boston, MA) CD14⁺CD34⁺ cells or DC through HUVEC, isolated and cultured as described (22) and used within four passages, or Matrigel (Collaborative Research Biomedical Products, Bedford, MA) was performed with the Transwell cell culture chambers (polycarbonate filters, 5 µm pore size; Costar, Cambridge, MA) in RPMI 1640 containing 1% Nutridoma (Boehringer Mannheim, Mannheim, Germany) as described (19, 20). When indicated, 100 ng/ml of the chemokines RANTES, MIP-1, or MIP-3 (kind gift of P. Allavena, Istituto Farmacologico M. Negri, Milan, Italy) (24), 100 µg/ml amiloride (Sigma), 10 µg/ml aprotinine (Bayer Trasylol, Zurich, Switzerland), or 0.1 mM plasmin-free plasminogen (Sigma) were added at the beginning of the transmigration assay (19). In other experiments, DC were incubated with the anti-CD18/₂ integrin mAb TS1.18 (American Type Culture Collection, Manassas, VA) or with blocking or nonblocking anti-uPAR Abs (R3 or R2, respectively; 5 µg/ml). Alternatively, DC were treated with 100 ng/ml TNF- during the transmigration assay or exposed to TNF- for 4, 12, or 24 h before transmigration (19). After 8 h of incubation (kinetics experiments show that after 8 h migration reached a plateau with a random migration of 10% or less (Table I)), migrated cells were recovered from the lower compartment and lysed with 100 mM Tris buffer containing 0.1% Triton X-100. The radioactivity of the samples was measured in a gamma-counter (Packard, Sterling, VA). Reverse transmigration was performed following the method described by Randolph et al. (24) partially modified according to D’Amico et al. (25) in the absence or presence of the R2 or R3 mAbs. Briefly, ECM was prepared by growing a monolayer of HUVEC on an upper polycarbonate filter (5-µm pores). After 5 days the monolayer was stripped by a 30-s treatment with a 20-mmol/L NH₄OH solution + 0.5% Triton X-100 (Sigma). The lower polycarbonate filter was placed upside down, coated by a monolayer of the same line of HUVEC, and mounted in a Boyden chamber. ⁵¹Cr-labeled DC were seeded on the upper compartment and the chamber was placed in an incubator at 37°C. After 4 h the migrated cells were recovered from the lower compartment, lysed, and counted in a gamma-counter. The relative percentage was calculated by comparing this value to that obtained by the lysis and the counting of the total original input. Statistical analysis was performed using the Student t test.

DC cultured with GM-CSF alone for 7 days or with TNF- during the last 48 h were used as stimulators for allogenic or tetanus-toxoid- (TT; gift of S. Burastero, HSR-Dibit, Milan, Italy) specific T lymphocytes as previouly reported (20). About 5 x 10⁴ allogeneic or TT-specific autologous T cells were added to irradiated (4000 rad) DC (from 10³ to 2 x 10⁴) in 96-well round-bottom microwell plates. For TT presentation, DC were loaded with the Ag for 24 h before the addition of specific T cells (20). After 3 days for the allogeneic reaction (MLR) or after 48 h for TT-specific response, cells were pulsed with 1 µCi of [³H]TdR (NEN-DuPont) per well for the last 18 h of culture, harvested, and counted in a beta-counter (Packard). Tests were conducted in triplicate and results are expressed as mean cpm ± S.D. [³H]TdR uptake by stimulatory DC or responder T cells alone was <400 cpm (data not shown).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Immature DC from CD14⁺CD34⁺ precursors use the uPA/uPAR system to invade ECM

As DC derived from CD14⁺CD34⁺ precursors upon culture with GM-CSF are capable of transendothelial migration (20), we addressed the question of whether they can also actively migrate through the subendothelial matrix. To this purpose, transmigration was performed in a two-chamber Transwell system after coating of the porous membrane with Matrigel, as an equivalent for ECM, in the absence of serum. Fig. 1 shows that a sizeable fraction of immature DC (cultured in GM-CSF for 5 days) can efficiently invade Matrigel in the absence of added chemokines, suggesting an alternative mechanism capable of driving transmigration. A similar effect has been described for the uPA/uPAR system in leukocytes, in which uPA/uPAR interaction activates the receptor which acts as a chemoattractant (18). Interestingly, we found that migration through Matrigel was significantly impaired when immature DC (Fig. 1) were pretreated with the anti-uPAR R3 mAb directed against the uPA binding site of uPAR, but it was not impaired with the nonblocking R2 mAb. A similar trend was observed using CD14⁺CD34⁺ DC precursors (data not shown).

View larger version (26K): [in this window] [in a new window]   FIGURE 1. Involvement of uPAR in the migration of immature DC through ECM. Immature DC derived from peripheral blood CD14+CD34+ precursors were radiolabeled and assayed for migration through Matrigel in a two-chamber Transwell system, in the absence () or presence () of plasmin-free plasminogen (0.1 mM) and before or after treatment with amiloride (100 µg/ml) or aprotinine (10 µg/ml) or with the anti-uPAR R3 or R2 mAbs (5 µg/ml), as indicated. After 8 h, migrated cells were recovered from the lower compartment and lysed. The radioactivity of the samples was measured in a gamma-counter. Results are expressed as percent migrating cells (mean ± SD from 10 independent experiments). *, p < 0. 05 vs the control without plasminogen; **, p < 0. 05 vs the control with plasminogen.

uPA/uPAR usage by immature DC in transendothelial migration

We found that immature DC can penetrate endothelial cell monolayers using the uPA/uPAR system, as shown by the fact that the blocking R3 mAb can reduce their transmigration through HUVEC monolayers (Fig. 2A). However, the involvement of such a system is less evident than using Matrigel, possibly because in vitro-cultured endothelial cells usually produce low amounts of subendothelial matrix, thus masking the real contribution of the uPA/uPAR system in a direct transmigration assay. Moreover, a wide number of adhesion molecules, both for endothelial cells and matrix ligands, are operating during transmigration. Because there is evidence that chemotaxis stimulated by uPAR is mediated, at least in part, by ₂ integrin activation (26, 27, 28), the relative role of CD18/₂ integrin and uPA/uPAR in transendothelial migration by DC has been investigated. As depicted in Fig. 2A, while both R3 and an anti-CD18 mAb can decrease the percentage of migrating DC, no additive effect is observed using the two mAbs. This might be due to the fact that our DC population, as we reported for their precursors (20), preferentially uses other adhesion systems involved in transmigration rather than CD18/ICAM-1. Because immature DC have been reported to migrate across endothelial monolayers, also in the basal-apical direction (24, 25), we investigated the role of uPA/uPAR in a reverse transmigration assay. Fig. 2B shows that immature DC can efficiently reverse transmigrate across HUVEC. Interestingly, the blocking anti-uPAR R3 mAb, at variance with the nonblocking R2 mAb, could significantly inhibit reverse transmigration (Fig. 2B), suggesting that the uPA/uPAR system contributes to the motility and recirculating potential of immature DC.

View larger version (30K): [in this window] [in a new window]   FIGURE 2. Involvement of uPAR in direct and reverse transendothelial migration of immature DC. Immature DC (cultured in GM-CSF for 5 days) were radiolabeled and assayed for direct (A) or indirect (B) migration through confluent HUVEC in a two-chamber Transwell system, without or with the anti-uPAR R3, or R2 or the anti-CD18/2 integrin mAbs (5 µg/ml), alone or in combination as indicated. After 4 h, migrated cells were recovered from the lower compartment and lysed. The radioactivity of the samples was measured in a gamma-counter. Results are expressed as percent migrating cells (mean ± SD from three independent experiments). *, p < 0.05 vs the control.

The CC chemokines RANTES and MIP-1 overcome the use of uPA/uPAR in immature DC

Recently, it has been reported that immature DC respond to selected CC chemokines, including RANTES and MIP-1, enhancing their chemotaxis and transendothelial migration (29, 30, 31). Thus, we addressed the questions of whether and how the use of the uPA/uPAR system by immature DC is regulated when matrix invasion is tested in the presence of RANTES or MIP-1. As shown in Fig. 3A, immature DC derived from CD14⁺CD34⁺ precursors are responsive to MIP-1, enhancing their transmigration through Matrigel by 50%. A lesser increase in transmigration (10%) was found in response to RANTES (Fig. 3A). Interestingly, MIP-1 was also capable of preventing the decreased matrix invasion due to the inhibitory effect of the anti-uPAR R3 mAb; however, the inhibitory effect of the Ab was not fully reverted by the MIP-1 (Fig. 3A), suggesting that the chemokine stimulates DC migration via alternative/additional pathways not influenced by uPAR and therefore not blocked by R3 mAb. In the presence of plasminogen, whereby the uPA/uPAR system is enhanced, the effect of MIP-1 was much less evident, and that of RANTES was absent (Fig. 3B).

View larger version (38K): [in this window] [in a new window]   FIGURE 3. Effect of the CC chemokines RANTES and MIP-1 on uPA/uPAR usage by immature DC. Transmigration through Matrigel was performed as in Fig. 1, in the absence (A) or presence (B) of plasmin-free plasminogen (0.1 mM) and without or with the addition of 100 ng/ml RANTES or MIP-1 to Matrigel. When indicated, DC were treated with the anti-uPAR R3 mAb (5 µg/ml). After 8 h, migrated cells were recovered from the lower compartment and lysed. The radioactivity of the samples was measured in a gamma-counter. Results are expressed as percent migrating cells (mean ± SD from four independent experiments). *, p < 0.05 vs the control without chemokines; **, p < 0.05 vs the control with chemokines.

It is known that upon maturation DC lose their response to chemokines and change their migratory pattern (30, 31). Thus, we studied the effects of TNF-, which contributes to DC differentiation (4, 5, 9, 21), on DC derived from CD14⁺CD34⁺ precursors. First, we found that these cells undergo maturation upon exposure to TNF- for 48 h after 5 days of culture in GM-CSF; indeed, they up-regulate costimulatory molecules, such as CD86/B7.2, HLA-DR, and to a lesser extent CD80/B7.1 and CD54/ICAM-1 (Fig. 4A). Expression of other surface molecules, such as ₁, ₂, or ₃ integrins, was not significantly altered upon maturation (data not shown). Because these phenotypic changes represent a hallmark of differentiation toward fully mature DC (4, 11, 12), we analyzed the immunostimulatory capacity of DC derived from GM-CSF cell culture (5 days) with or without TNF- for an additional 48 h. To this aim, the two DC populations were used as stimulators to TT-specific T cell lines. As shown in Fig. 4B, TNF--treated DC pulsed with TT increased their capacity for stimulating the proliferation of TT-specific T lymphocytes. As shown in Fig. 4C, this phenomenon was even more evident in allogenic stimulation (MLR). Thus, DC derived from CD14⁺CD34⁺ precursors respond to maturative stimuli and potentiate their APC function, a response similar to those of other DC populations. Interestingly, upon maturation induced by TNF-, DC significantly reduced their capacity for invading ECM in vitro, both in the absence and in the presence of plasminogen (compare Fig. 5A with Fig. 1; p < 0.05). Migration was decreased by DC treatment with amiloride and aprotinin (although to a lesser extent than in immature DC; compare Fig. 5A to Fig. 1), but not with the R3 anti-uPAR Ab (Fig. 5A). These data suggest that the uPA/uPAR system is less active in mature DC than in immature DC.

View larger version (21K): [in this window] [in a new window]   FIGURE 4. Enhancement of Ag-specific functions by mature DC. A, Up-regulation of costimulatory molecules upon maturation. Immature (GM-CSF for 7 days; ) or mature (GM-CSF for 7 days plus TNF- during the last 48 h; ) DC were stained with the relevant mAbs and then with the anti-isotype-specific FITC-conjugated GAM. Samples were then run (5000 events/sample) on a FACStarPlus (Becton Dickinson). Results are expressed as the mean of green fluorescence intensity (in a.u.) and are the mean ± SD from six independent experiments. Proliferation of TT-specific T cell lines (B) or allogenic T cells (C) to immature () or mature () DC. After 3 days for MLR or 48 h for TT-specific stimulation, cells were pulsed with 1 µCi of [3H]TdR per well for the last 18 h of culture, harvested, and counted in a beta-counter. Results are mean cpm ± SD from six independent experiments. [3H]TdR uptake by stimulatory DC alone was <100 cpm. [3H]TdR uptake by allogenic or TT-specific T cell lines alone was <400 cpm.

View larger version (21K): [in this window] [in a new window]   FIGURE 5. Down-regulation of the uPA/uPAR system in the migration of mature DC through ECM. DC cultured in GM-CSF for 7 days and exposed to TNF- for the last 48 h, were radiolabeled and assayed for migration through Matrigel in a two-chamber Transwell system. A, migration in the absence () or presence () of plasmin-free plasminogen (0.1 mM) and before or after treatment with amiloride (100 µg/ml) or aprotinine (10 µg/ml) or with the anti-uPAR R3 or R2 mAbs (5 µg/ml) as indicated. *, p < 0. 05 vs the control without plasminogen. B, Migration as in A (without plasminogen) in the absence or presence of MIP-3 (100 ng/ml), R3 mAb, or both, as indicated. *, p < 0.05 vs the control without MIP-3. After 8 h, migrated cells were recovered from the lower compartment and lysed. The radioactivity of the samples was measured in a gamma-counter. Results are expressed as percent migrating cells (mean ± SD from 10 independent experiments).<. >

MIP-3 can drive matrix invasion by mature DC

Because it has been reported that the sensitivity of DC shifts from MIP-1 to MIP-3 upon maturation (29, 30, 31), we addressed the question of whether this chemokine could stimulate migration of mature DC through Matrigel. Fig. 5B shows that mature DC derived from CD34⁺CD14^- precursors respond to MIP-3 and enhance their capability for invading ECM. Moreover, R3 mAb does not interfere with MIP-3-driven migration of mature DC through Matrigel (Fig. 5B). However, it has to be noted that uPAR is less functional in mature DC (see above and Fig. 5A).

In another series of experiments, migration through Matrigel was tested using immature DC treated with TNF- for less than 2 days. A short exposure (4 h) of DC to TNF- enhanced Matrigel invasion (at variance with treatment for 12 h or 24 h) without significantly affecting uPAR expression (data not shown). The presence of the cytokine during migration assay did not alter the degree or rate of transmigration (Fig. 6). This suggests that DC can move in response to TNF- when immature and then become less sensitive and decrease their motility upon exposure to maturative stimuli.

View larger version (37K): [in this window] [in a new window]   FIGURE 6. Effect of TNF- on ECM invasion by DC. Transmigration of radiolabeled immature DC through Matrigel was performed as in Fig. 1, without () or with () the addition of 100 ng/ml of TNF-. When indicated, DC were pretreated with the cytokine for different periods of time and washed before starting the transmigration assay. After 8 h, migrated cells were recovered from the lower compartment and lysed. The radioactivity of the samples was measured in a gamma-counter. Results are expressed as percent migrating cells (mean ± SD from four independent experiments).

We asked whether the decreased usage of the uPA/uPAR system in matrix invasion was due, at least in part, to changes in uPAR expression and/or surface distribution in mature vs immature DC. Fig. 7A shows that uPAR is detectable by indirect immunofluorescence on DC derived from 7-day cultures with GM-CSF; treatment with TNF- for the last 48 h decreased its intensity of expression (Fig. 7B). Apparently, this was not due to the shedding of uPAR; indeed, the amount of the receptor detectable by ELISA in the supernatants of DC cultured in GM-CSF did not change after exposure to TNF- (Fig. 7C). As expected, treatment of immature or mature DC with PI-PLC, an enzyme that cleaves phosphoinositide bridges whereby uPAR is linked to the cell surface (32), led to the release of detectable amounts of uPAR (Fig. 7C).

View larger version (22K): [in this window] [in a new window]   FIGURE 7. uPAR surface expression is down-regulated on DC upon maturation. A and B, uPAR surface expression by DC derived upon culture with GM-CSF alone for 7 days (M1 in A) or treated with TNF- for the last 48 h (M1 in B). A total of 105 cells/sample were fixed and stained with the anti-uPAR mAb and then with the anti-isotype-specific FITC-conjugated GAM. Samples were then run (5000 events/sample) on a FACStarPlus (Becton Dickinson). Results are expressed as the mean of green fluorescence intensity (in a.u.) and are the mean ± SD from 10 independent experiments. C, Measurement by ELISA of uPAR in the supernatants of DC cultured with GM-CSF or TNF- alone for 5 days, cultured in GM-CSF and treated with TNF- for an additional 48 h, or washed and exposed to PI-PLC (2 U/ml at 37°C) for 2 h. Results are expressed as pg/106 cells and are the mean ± SD from four independent experiments.

View larger version (81K): [in this window] [in a new window]   FIGURE 8. Different distribution of uPAR in mature or immature DC. Confocal microscopy performed on GM-CSF-cultured DC, before (immature DC) and after (mature DC) exposure to TNF- for the last 48 h. A, uPAR localization at the top of filopodia in DC cultured in GM-CSF. B, uPAR surface distribution in TNF--treated DC. C and D, Surface distribution of HLA-DR on immature (C) or mature (D) DC. Fluorescence images were recorded on Kodak T-Max 100 film.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

DC precursors migrate from bone marrow toward peripheral tissues using multiple adhesion systems that allow them to stick and detach to vascular endothelium and subendothelial matrix to reach their final destination (11, 12). From this viewpoint uPA/uPAR might represent a useful tool for shifting from transendothelial to subendothelial migration; indeed, upon binding to uPAR, pro-uPA is changed into its active form that converts plasminogen into plasmin which, in turn, can degrade fibrin and other proteins, thus driving cell migration through the extracellular milieu (18, 33, 34, 35). The activation of this enzymatic system may contribute to completing the cell polarization that begins when DC migrate between endothelial cells, maintaining a directional movement through subendothelial matrix toward the final destination. Support for this hypothesis comes from our observation that DC can use the uPA/uPAR system to migrate across HUVEC monolayers. Interestingly, we found that uPA/uPAR is involved in the reverse transmigration of immature DC as well, thus possibly contributing to their recirculating potential. The finding that immature DC respond to MIP-1, enhancing their ability to invade ECM, supports the idea that DC are selectively driven at the site of inflammation, possibly where the Ag is present at high concentrations, which is in agreement with other reports (29, 30, 31). Interestingly, MIP-1 was also capable of preventing the decreased matrix invasion observed by blocking uPAR, suggesting that the uPA/uPAR system and MIP-1 cooperate in driving immature DC migration through the subendothelial matrix.

When DC undergo maturation, they usually down-regulate most of surface chemokine receptors, shifting their sensitivity toward other chemokines such as MIP-3 (30, 31). In keeping with this, we found that mature DC derived from CD34⁺CD14⁺ precursors do not respond to MIP-1, acquiring the ability to migrate in response to MIP-3. Moreover, uPAR is down-regulated at the cell surface and the uPA/uPAR sytem is less active in mature DC. From this viewpoint, our data are in line with the hypothesis that leukocytes can respond sequentially to chemokines in a "multistep navigation" mode (38).

However, it is largely accepted that, after capture of the Ag, mature DC also travel to the lymphoid tissues where they encounter T lymphocytes (2, 10, 12). DC are also detectable in the afferent lymph and in the absence of pathogens or tissue injuries (12). Thus, it is conceivable that immature DC can move actively in the inflamed tissue until they reach the site of pathogen entry, where they undergo complete maturation. In this timeframe, their motility might be modulated by microenvironmental stimuli, such as chemokines and/or cytokines, released during inflammation. Such factors include TNF-, which is involved in DC maturation.

TNF- has been reported to promote DC migration in mice (39, 40). However, it should be noted that when these phenomena are evaluated in vivo, the overall effect of the cytokine on both migrating cells and neighboring tissues, including endothelium, are considered. The majority of the reported effects of TNF- on cell migration are referred to its action on endothelial cells; indeed, this cytokine can increase vascular permeability, induce proinflammatory cytokine production by endothelial cells themselves, and regulate the expression of adhesion and junctional molecules (22, 41, 42, 43). We found that TNF- up-regulates costimulatory molecules on immature DC and enhances Ag presentation; in turn, it down-regulates the expression and function of uPA/uPAR, thus contributing to the decreased motility of DC during maturation, in line with data from the literature (30, 31). However, when used as a short-term challenge, TNF- can potentiate matrix invasion. It is tempting to speculate that immature DC actively respond to different chemotactic stimuli until they undergo maturation and then become less motile and remain in the tissue as long as the pathogen is present to complete Ag capture. This is in line with reported data showing that mature DC are less motile than immature DC (30, 31).

After capturing the Ag, mature DC should reacquire the ability of traverse the endothelium in the abluminal-luminal direction to reach lymph nodes and initiate T cell-dependent immune responses. Evidence has been reported for the so-called reverse transmigration by either immature or mature DC (25, 29, 30). During this process mature DC use adhesion/migratory pathways other than those used by immature DC and their precursors (29, 30). This might explain our observation that the CD18/₂ integrin is poorly functional in immature DC and does not seem to cooperate with the uPA/uPAR system in driving transendothelial migration. Along this line we found that while transendothelial migration of CD14⁺CD34⁺ precursors seems to be preferentially driven by a CD31 aptotactic gradient (20), mature DC shift to VCAM-1-driven transmigration (data not shown), possibly favoring the reverse transmigration. The down-regulation of the uPA/uPAR system might be useful to enhance this process, thus allowing the detachment from matrix and permitting mature DC recirculation.

	Acknowledgments

 
We thank C. Rugarli and F. Blasi for support, A. Rubartelli for critical reading of the manuscript, and G. Consogno for skillful technical assistance. We are also grateful to R. Accolla (Advanced Biotechnology Center, Genoa, Italy), P. Allavena (Istituto Framacologico M. Negri, Milan, Italy), and E. Rønne and G. Høyer-Hanse (K. Danø Finsen Laboratory, Copenhagen, Denmark) for sharing their reagents.

	Footnotes

 
¹ This work was partially supported by the Italian Ministry of Health (Programma per la Ricerca Finalizzata, to M.R.Z. and A.P.), by the Giovanni Armenise-Harvard Foundation (to A.V.), and by the Associazione Italiana per la Ricerca sul Cancro.

² Address correspondence and reprint requests to Dr. Elisabetta Ferrero, Laboratory of Tumor Immunology, Scientific Institute San Raffaele, Via Olgettina 60, I-20132 Milan, Italy. E-mail address:

³ Abbreviations used in this paper: DC, dendritic cells; ECM, extracellular matrix; MIP, macrophage-inflammatory protein; GAM, goat anti-mouse Igs; PI-PLC, phosphoinositide-specific pospholipase C; TT, tetanus toxoid; uPA, urokinase plasminogen activator; a.u., arbitrary units.<. >

Received for publication May 27, 1999. Accepted for publication November 4, 1999.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Van Furth, R., Z. A. Cohn. 1968. The origin and kinetics of mononuclear phagocytes. J. Exp. Med. 128:415.[Abstract]
2. Austyn, J. M.. 1996. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 183:1287.[Free Full Text]
3. Ogawa, M.. 1993. Differentiation and proliferation of hemopoietic stem cells. Blood 81:2844.[Abstract/Free Full Text]
4. Cella, M., F. Sallusto, A. Lanzavecchia. 1997. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:10.[Medline]
5. Caux, C., B. Vanbervliet, C. Massacrier, C. Dezutter-Dambuyant, B. de Saint-Vis, C. Jaquet, K. Yoneda, S. Imamura, D. Schmitt, J. Bancherau. 1996. CD34⁺ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF. J. Exp. Med. 184:695.[Abstract/Free Full Text]
6. Szabolcs, P., M. A. S. Moore, J. W. Young. 1995. Expansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34⁺ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor and TNF-. J. Immunol. 154:5851.[Abstract]
7. Peters, J. H., R. Giesler, B. Thiele, F. Steinbach. 1996. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol. Today 17:273.[Medline]
8. Knight, S., S. Patterson. 1997. Bone marrow-derived dendritic cells, infection with human immunodeficiency virus, and immunopathology. Annu. Rev. Immunol. 15:593.[Medline]
9. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, I. Durand, M. Cella, A. Lanzavecchia, J. Bancherau. 1997. CD34⁺ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor . II. Functional analysis. Blood 90:1458.[Abstract/Free Full Text]
10. Steinman, R. M.. 1991. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271.[Medline]
11. Caux, C., Y.-J. Liu, J. Bancherau. 1995. Recent advances in the study of dendritic cells and follicular dendritic cells. Immunol. Today 16:23.
12. Bancherau, J., R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:247.
13. Butcher, E. C.. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell 67:1033.[Medline]
14. Hynes, R. O.. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11.[Medline]
15. Springer, T. A.. 1990. Adhesion receptors of the immune system. Nature 346:425.[Medline]
16. Dunon, D., L. Piali, B. A. Imhof. 1996. To stick or not to stick: the new leukocyte homing paradigm. Curr. Opin. Cell Biol. 8:714.[Medline]
17. Ratner, S.. 1992. Lymphocyte migration through extracellular matrix. Invasion Metastasis 12:82.[Medline]
18. Bianchi, E., J. R. Bender, F. Blasi, R. Pardi. 1997. Through and beyond the wall: late steps in leukocyte transendothelial migration. Immunol. Today 18:586.[Medline]
19. Bianchi, E., E. Ferrero, F. Fazioli, F. Mangili, J. Wang, J. R. Bender, F. Blasi, R. Pardi. 1996. Integrin-dependent induction of functional urokinase receptors in primary lymphocytes. J. Clin. Invest. 98:1133.[Medline]
20. Ferrero, E., A. Bondanza, B. E. Leone, S. Manici, A. Poggi, M. R. Zocchi. 1998. CD14⁺CD34⁺ peripheral blood mononuclear cells migrate across endothelium and give rise to immunostimulatory dendritic cells. J. Immunol. 160:2675.[Abstract/Free Full Text]
21. Cella, M., A. Engering, V. Pinet, J. Pieters, A. Lanzavecchia. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782.[Medline]
22. Ferrero, E., A. Villa, M. E. Ferrero, E. Toninelli, J. R. Bender, R. Pardi, M. R. Zocchi. 1996. Tumor necrosis factor -induced vascular leakage involves PECAM1 phosphorylation. Cancer Res. 56:3211.[Abstract/Free Full Text]
23. Rønne, E., N. Behrendt, M. Plough, H. J. Nielsen, E. Wollish, V. Weidle, K. Danø, G. Høyer-Hansen. 1994. Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked immunosorbent assay. J. Immunol. Methods 167:91.[Medline]
24. Randolph, G. J., S. Beaulieu, S. Lebecque, R. M. Steinman, W. A. Muller. 1998. Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science 282:480.[Abstract/Free Full Text]
25. D’Amico, G., G. Bianchi, S. Bernasconi, L. Bersani, L. Piemonti, S. Sozzani, A. Mantovani, P. Allavena. 1998. Adhesion, transendothelial migration and reverse transmigration of in vitro cultured dendritic cells. Blood 92:207.[Abstract/Free Full Text]
26. Sitrin, R. G., R. F. Todd, H. R. Petty, T. G. Brock, S. B. Shollenberger, E. Albrecht, M. R. Gyetko. 1996. The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J. Clin. Invest. 97:1942.[Medline]
27. May, A. E., S. M. Kanse, L. R. Lund, R. H. Gisler, B. A. Imhof, K. T. Preissner. 1998. Urokinase receptor (CD87) regulates leukocyte recruitment via ₂ integrins in vivo. J. Exp. Med. 188:1029.[Abstract/Free Full Text]
28. Bohuslav, J., V. Horejsì, C. Hansmann, J. Stoeckl, U. H. Weidle, O. Majdic, I. Bartke, W. Knapp, H. Stockinger. 1995. Urokinase plasminogen activator receptor, ₂-integrins, and Src-kinases within a single receptor complex of human monocytes. J. Exp. Med. 181:1381.[Abstract/Free Full Text]
29. Sozzani, S., W. Luini, A. Borsatti, N. Polentarutti, D. Zhou, L. Piemonti, G. D’Amico, C. A. Power, T. N. C. Wells, M. Gobbi, et al 1997. Receptor expression and responsiveness of human dendritic cells to a defined set of CC and CXC chemokines. J. Immunol. 159:1993.[Abstract]
30. Dieu, M. C., B. Vanbervliet, A. Vicari, J. M. Bridon, E. Oldham, S. Aìt-Yahia, F. Brière, A. Zlotnik, S. Lebecque, C. Caux. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med. 188:373.[Abstract/Free Full Text]
31. Sozzani, S., P. Allavena, G. D’Amico, W. Luini, G. Bianchi, M. Kataura, T. Imai, O. Yoshie, R. Bonecchi, A. Mantovani. 1998. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. 161:1083.[Abstract/Free Full Text]
32. Resnati, M., M. Guttinger, S. Valcamonica, N. Sidenius, F. Blasi, F. Fazioli. 1996. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J. 15:1572.[Medline]
33. Estreicher, A., J. Mulhauser, J.-L. Carpentier, L. Orci, J.-D. Vassalli. 1990. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitors complexes. J. Cell Biol. 111:783.[Abstract/Free Full Text]
34. Fazioli, F., M. Resnati, N. Sidenius, Y. Higashimoto, E. Appella, F. Blasi. 1997. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 16:7279.[Medline]
35. Porter, J., N. Hogg. 1998. Integrins take partners: cross-talk between integrin and other membrane receptors. Trends Cell Biol. 8:390.[Medline]
36. Bristow, C. L., L. K. Lyford, D. P. Stevens, P. M. Flood. 1991. Elastase is a constitutive product of T cells. Biochem. Biophys. Res. Commun. 181:232.[Medline]
37. Leppert, D., E. Waubant, R. Galardy, N. W. Bunnet, S. L. Hauser. 1995. T cell gelatinase mediate basement membrane transmigration in vitro. J. Immunol. 154:4379.[Abstract]
38. Sallusto, F., A. Lanzavecchia, C. R. Mackay. 1998. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol. Today 19:568.[Medline]
39. Roake, J. A., A. S. Rao, P. J. Morris, C. P. Larsen, D. F. Hankins, M. Austin. 1995. Dendritic cell loss from non lymphoid tissues following systemic administration of lipopolysaccharide, tumor necrosis factors and interleukin-1. J. Exp. Med. 181:2237.[Abstract/Free Full Text]
40. MacPherson, G. G., C. D. Jenkins, M. J. Stein, C. Edwards. 1995. Endotoxin-mediated dendritic cell release from the intestine: characterization of released dendritic cells and TNF dependence. J. Immunol. 154:1317.[Abstract]
41. Goldblum, S. E., X. Ding, J. Campbell-Johnson. 1993. TNF- induces endothelial cell F-actin depolimerization, new actin synthesis, and barrier dysfunction. Am. Cell. Physiol. 264:C894.
42. Romer, L. H., N. V. McLean, H.-C. Yan, M. Daise, H. M. DeLisser. 1995. IFN- and TNF- induce redistribution of PECAM-1 (CD31) on human ECs. J. Immunol. 154:6582.[Abstract]
43. Mantovani, A., S. Sozzani, A. Vecchi, M. Introna, P. Allavena. 1997. Cytokine activation of endothelial cells: new molecules for an old paradigm. Thromb. Haemostasis. 78:406.[Medline]

This article has been cited by other articles:

				D. Ilkovitch and D. M. Lopez Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec Blood, May 7, 2009; 113(19): 4729 - 4739. [Abstract] [Full Text] [PDF]

				D. Ilkovitch, M. E. Handel-Fernandez, L. M. Herbert, and D. M. Lopez Antitumor Effects of Mucin 1/sec Involves the Modulation of Urokinase-Type Plasminogen Activator and Signal Transducer and Activator of Transcription 1 Expression in Tumor Cells Cancer Res., April 1, 2008; 68(7): 2427 - 2435. [Abstract] [Full Text] [PDF]

				V. Chabot, P. Reverdiau, S. Iochmann, A. Rico, D. Senecal, C. Goupille, P.-Y. Sizaret, and L. Sensebe CCL5-enhanced human immature dendritic cell migration through the basement membrane in vitro depends on matrix metalloproteinase-9 J. Leukoc. Biol., April 1, 2006; 79(4): 767 - 778. [Abstract] [Full Text] [PDF]

				M. Alfano, N. Sidenius, F. Blasi, and G. Poli The role of urokinase-type plasminogen activator (uPA)/uPA receptor in HIV-1 infection J. Leukoc. Biol., November 1, 2003; 74(5): 750 - 756. [Abstract] [Full Text] [PDF]

				E. Ferrero, D. Belloni, P. Contini, C. Foglieni, M. E. Ferrero, M. Fabbri, A. Poggi, and M. R. Zocchi Transendothelial migration leads to protection from starvation-induced apoptosis in CD34+CD14+ circulating precursors: evidence for PECAM-1 involvement through Akt/PKB activation Blood, January 1, 2003; 101(1): 186 - 193. [Abstract] [Full Text] [PDF]

				M. Alfano, N. Sidenius, B. Panzeri, F. Blasi, and G. Poli Urokinase-urokinase receptor interaction mediates an inhibitory signal for HIV-1 replication PNAS, June 25, 2002; 99(13): 8862 - 8867. [Abstract] [Full Text] [PDF]

				Y. Wei, J. A. Eble, Z. Wang, J. A. Kreidberg, and H. A. Chapman Urokinase Receptors Promote beta 1 Integrin Function through Interactions with Integrin alpha 3beta 1 Mol. Biol. Cell, October 1, 2001; 12(10): 2975 - 2986. [Abstract] [Full Text] [PDF]

				E. Grage-Griebenow, H.-D. Flad, and M. Ernst Heterogeneity of human peripheral blood monocyte subsets J. Leukoc. Biol., January 1, 2001; 69(1): 11 - 20. [Abstract] [Full Text]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferrero, E. Articles by Zocchi, M. R. Search for Related Content PubMed PubMed Citation Articles by Ferrero, E. Articles by Zocchi, M. R.